Innogen · News · June 4, 2010

Funding Success for Innogen, in partnership with consortium lead by the Scottish Stem Cell Network

Cells 3

£444,000 award was made under the Technology Strategy Board Regenerative Medicine Programme: Value Systems and Business Models.

The project, "A Therapy Realization Pathway Tool (TRPT) applied to three representative regenerative medicine therapeutic products (REALISE)" will be led by the Scottish Stem Cell Network (SSCN) on behalf of a consortium which involves Roslin Cells Ltd. and KLCE Consulting Ltd, Innogen and other University of Edinburgh academics.

The REALISE project will develop a software based tool that researchers and companies will be able to use to better understand and plan the optimal route for the commercialisation of new regenerative medicine therapies. This will be used in the first instance to develop commercialisation plans for three new therapies currently in development with Roslin Cells. In addition, it will form the basis of a generic tool with wider applicability across the pharmaceutical, medical device and diagnostic sectors. The project will run from 1st May 2010 – 31st October 2011.

The award to the University of Edinburgh was £192,569. For our part of the project, , , , and from Innogen, along with Dr Geoff Gregson (Edinburgh University Business School) and Dr David Hay (Centre for Regenerative Medicine) will adopt a scenario-based approach, involving the TRPT, to evaluate a range of business plans and value systems and test their robustness under various regulatory and funding contingencies.